Citron Research Out Negative on J2 Global (JCOM)

Go back to Citron Research Out Negative on J2 Global (JCOM)

Early Valeant/Walgreens Boots Prescription Trends Continuing to Look Positive - Guggenheim (VRX) (WBA)

March 11, 2016 9:37 AM UTC

Guggenheim affirms Valeant Pharma (NYSE: VRX) with a Buy rating and $145 price target following recent dermatology prescription performance checks.

Analyst Louise Chen noted the following on Friday:

VRX dermatology Rxs reached ~80% of their levels prior to any disruption from Philidor (October '15) levels up from ~75% last week. TRx's for derm... More

J2 Global (JCOM) Comments on Citron Report; Calls 'Factually Incorrect'

March 11, 2016 6:06 AM UTC

j2 Global, Inc. (Nasdaq: JCOM). j2 is aware of a report issued yesterday that we believe is both factually incorrect and wrongly... More

UPDATE: Is J2 Global (JCOM) Short a Blast from the Past?

March 10, 2016 2:06 PM UTC

(Updated - March 10, 2016 3:04 PM EST)

Some traders are suggesting Citron Research was recommending a short on J2 Global (NASDAQ: JCOM) 10 years ago when it was Stocklemon. It is unclear if this is the case. Shares are hitting the lows of the session down 20%... More

J2 Global (JCOM) Shares Dip

March 10, 2016 11:48 AM UTC

J2 Global (NASDAQ: JCOM) Shares Dip

... More